A widely distributed gene cluster compensates for uricase loss in hominids
Cell, ISSN: 0092-8674, Vol: 186, Issue: 16, Page: 3400-3413.e20
2023
- 46Citations
- 48Captures
- 8Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations46
- Citation Indexes46
- 46
- CrossRef32
- Captures48
- Readers48
- 48
- Mentions8
- News Mentions6
- News6
- References2
- Wikipedia2
Most Recent News
Every Cure to Leverage Atropos Health’s GENEVA OS and Evidence Network to Advance the Discovery and Development of Therapies for Underserved Populations
New Partnership Enables Real World Data Confirmation of Drug Repurposing Opportunities and Trial Emulation Capabilities to Speed Clinical Development PALO ALTO, Calif.–(BUSINESS WIRE)–Atropos Health, the
Article Description
Approximately 15% of US adults have circulating levels of uric acid above its solubility limit, which is causally linked to the disease gout. In most mammals, uric acid elimination is facilitated by the enzyme uricase. However, human uricase is a pseudogene, having been inactivated early in hominid evolution. Though it has long been known that uric acid is eliminated in the gut, the role of the gut microbiota in hyperuricemia has not been studied. Here, we identify a widely distributed bacterial gene cluster that encodes a pathway for uric acid degradation. Stable isotope tracing demonstrates that gut bacteria metabolize uric acid to xanthine or short chain fatty acids. Ablation of the microbiota in uricase-deficient mice causes severe hyperuricemia, and anaerobe-targeted antibiotics increase the risk of gout in humans. These data reveal a role for the gut microbiota in uric acid excretion and highlight the potential for microbiome-targeted therapeutics in hyperuricemia.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0092867423006876; http://dx.doi.org/10.1016/j.cell.2023.06.010; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85166599099&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37541197; https://linkinghub.elsevier.com/retrieve/pii/S0092867423006876; https://dx.doi.org/10.1016/j.cell.2023.06.010
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know